Edition:
India

Avenue Therapeutics Inc (ATXI.OQ)

ATXI.OQ on NASDAQ Stock Exchange Capital Market

5.46USD
11 Oct 2019
Change (% chg)

$0.04 (+0.74%)
Prev Close
$5.42
Open
$5.40
Day's High
$5.59
Day's Low
$4.99
Volume
6,722
Avg. Vol
7,758
52-wk High
$7.95
52-wk Low
$2.10

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Q2 Loss Per Share $0.43
Wednesday, 14 Aug 2019 

Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.43.Q2 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.  Full Article

Avenue Therapeutics Says Second Pivotal Phase 3 Trial Of IV Tramadol Achieved Primary Endpoint
Monday, 3 Jun 2019 

June 3 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM SECOND PIVOTAL PHASE 3 STUDY OF INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - SECOND PIVOTAL PHASE 3 TRIAL OF IV TRAMADOL ACHIEVED PRIMARY ENDPOINT.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL..  Full Article

Avenue Therapeutics Q1 Loss Per Share $0.82
Monday, 13 May 2019 

Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q1 LOSS PER SHARE $0.82.Q1 EARNINGS PER SHARE ESTIMATE $-0.43 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, AVENUE'S CASH AND CASH EQUIVALENTS TOTALED $29.4 MILLION, COMPARED TO $2.7 MILLION AT DECEMBER 31, 2018.  Full Article

Avenue Therapeutics Reports Q2 Loss Per Share $0.45
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.45.AS OF JUNE 30, 2018, AVENUE'S CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $8.9 MILLION.  Full Article

Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain
Monday, 21 May 2018 

May 21 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - INITIATION OF SECOND PIVOTAL PHASE 3 TRIAL PLANNED FOR Q3 OF 2018.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL.AVENUE THERAPEUTICS INC - IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS.AVENUE THERAPEUTICS - ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019.  Full Article

Avenue Therapeutics Files For Mixed Shelf Offering Of Up To $75 Mln
Saturday, 14 Apr 2018 

April 13 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $75 MILLION - SEC FILING.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Avenue Therapeutics reports Q3 loss per share $0.30
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Avenue Therapeutics Inc :Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.30.  Full Article